1221793-42-5 Usage
General Description
1-(tert-butoxycarbonyl)-4,4-difluoropiperidine-2-carboxylic acid is a chemical compound with the molecular formula C13H19F2NO4. It is a carboxylic acid derivative that contains a piperidine ring with two fluorine atoms and a tert-butoxycarbonyl (Boc) protecting group. 1-(tert-butoxycarbonyl)-4,4-difluoropiperidine-2-carboxylic acid is commonly used in organic synthesis and medicinal chemistry as a building block for the synthesis of pharmaceuticals and other biologically active compounds. The Boc protecting group is used to temporarily mask the amino group of the piperidine ring during synthetic reactions, and can be removed under specific conditions to expose the free amine for further modification. The difluoropiperidine-2-carboxylic acid moiety may also impart unique chemical and biological properties to the molecules it is incorporated into.
Check Digit Verification of cas no
The CAS Registry Mumber 1221793-42-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,1,7,9 and 3 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1221793-42:
(9*1)+(8*2)+(7*2)+(6*1)+(5*7)+(4*9)+(3*3)+(2*4)+(1*2)=135
135 % 10 = 5
So 1221793-42-5 is a valid CAS Registry Number.
1221793-42-5Relevant articles and documents
Substituted piperidine amide derivative, preparation method thereof, and application of derivative to pharmacy
-
, (2017/08/30)
The invention relates to a substituted piperidine amide derivative as shown in a general formula (I) or a stereisomer and pharmaceutically acceptable salt thereof, a preparation method of the derivative, medicinal combination as well as application of the derivative to the aspects of local anaesthesia or analgesia. The definition of each group of the general formula (I) is consistent with that of the description. (The general formula (I) is as shown in the description).
INHIBITORS OF HEPATITIS C VIRUS
-
, (2012/01/05)
The present application includes novel inhibitors of HCV, compositions containing such compounds, therapeutic methods that include the administration of such compounds.
